CPEB1 and neoplasm: Encouraged by the above in vitro results, to further evaluate the effect of CPEB1 loss on ferroptosis susceptibility in vivo, we performed subcutaneous xenograft tumor models derived from JF-305 cells without or with CPEB1 knockout in nude mice, and treated the mice with erastin or vehicle, as shown in Figure 5A. We demonstrated that CPEB1-deficient tumors conferred remarkable resistance to erastin treatment, with less inhibition of tumor growth (Figure 5B) and a shorter doubling time in tumor size (Figure 5C), compared to their CPEB1-normal counterparts.